We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

Vertex Pharmaceuticals（纳斯达克代码：VRTX）执行副总裁兼首席科学官David Altshuler最近出售了3,231股公司普通股。此次交易于3月10日进行，每股售价为500美元，总交易价值约为160万美元。在交易发生时，该公司股票接近52周高点519.88美元，公司市值维持在1,272.3亿美元，年初至今回报率达21.27%。此次出售后，Altshuler仍持有26,51 ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

过去的十年对 Vertex Pharmaceuticals（VRTX） 来说是一个转折点。这家生物技术公司于2012年获得了首个囊性纤维化（CF）药物——Kalydeco的批准，并随后获得了另外四种药物的监管批准，成为CF市场的全球领导者。公司还展示了在这一专业领域之外的实力，一年多前获得了一种用于血液疾病的基因编辑疗法的批准，最近又获得了一种疼痛治疗的批准。 Vertex的CF药物组合帮助公司2 ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

投资者可以进行盘前（美国东部时间上午 4:00 - 9:30） 和盘后（美国东部时间下午 4:00 - 8:00） 交易。做市商和 ECN 严格自愿参与，因此，这些时段的 ...